Immune Response in Lung Cancer

Completed

• Conditions: Lung Cancer

• Registration Number: NCT01955343
• Lead Sponsor: Lithuanian University of Health Sciences

Brief Summary

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2013-09-27
• Study First Submitted QC: 2013-09-27
• Study First Posted: 2013-10-07
• Primary Completion: 2015-07
• Study Completion: 2016-03
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-22
• Last Update Posted: 2017-06-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) score of 0-1
• Patients with histologically documented non-small cell lung cancer
• Control group - patients without non-small cell lung cancer
• Written (signed) Informed Consent to participate in the study

Exclusion Criteria

• Any other malignancies within 5 years
• Any unstable systemic disease (including active infections, significant cardiovascular disease)
• Prior chemotherapy or radiotherapy
• Autoimmune disease
• Nursing or pregnant women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression-free survival	one year after enrolment to the study

Secondary Outcome Measures

Name	Time	Method
overall survival	3 years

Trial Locations

Locations (1)

Lithuanian University of Health Sciences; 🇱🇹 Kaunas, Lithuania